FOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion

Stock News

Oct 28

FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.

The year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.

The increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179075043"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179075043\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179075043?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179075043","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.</p>\n<p>The year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.</p>\n<p>The increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-28 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.</p>\n<p>The year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.</p>\n<p>The increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"","article_id":"1179075043","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179075043","pubTimestamp":1761642854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0187":"一线龙头","BK0060":"抗癌","BK0175":"白马股","BK0028":"国家队","BK0239":"医药制造","02196":"复星医药","BK0012":"证金概念","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0096":"民营医院","BK0188":"融资融券","BK1191":"制药","BK1593":"医美概念股","BK0196":"行业龙头"},"translate_title":"复星医药(02196)公布第三季度业绩：归属股东净利润同比增长25.5%至人民币25.2亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.\nThe year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.\nThe increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}